Sign in
EFTRW Stock Price, Chart, Stats & News
eFFECTOR Therapeutics, Inc.
Save
eFFECTOR Therapeutics, Inc. (EFTRW) does not currently pay a dividend.
941
Market cap
–
Current P/E
–
Forward P/E
EFTRW chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue